Loading…
Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C
Abstract Objective. The aim of this study was to examine the early viral kinetics as predictor for sustained virological response (SVR) during hepatitis C treatment. Materials and methods. We included patients with biopsy-proven chronic hepatitis C and ALT above the upper limit of normal, who receiv...
Saved in:
| Published in: | Scandinavian journal of gastroenterology 2012-09, Vol.47 (8-9), p.1115-1119 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c448t-ba0d36ed1fc8465010313bd3e48dbeed96a3df3eed0a2223e4dbb8c87ae19de3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c448t-ba0d36ed1fc8465010313bd3e48dbeed96a3df3eed0a2223e4dbb8c87ae19de3 |
| container_end_page | 1119 |
| container_issue | 8-9 |
| container_start_page | 1115 |
| container_title | Scandinavian journal of gastroenterology |
| container_volume | 47 |
| creator | Christensen, Peer Brehm Krarup, Henrik Bygum Laursen, Alex Lund Madsen, Poul Henning Pedersen, Court Schlichting, Poul Orholm, Marianne Ring-Larsen, Helmer Bukh, Jens Krogsgaard, Kim |
| description | Abstract
Objective.
The aim of this study was to examine the early viral kinetics as predictor for sustained virological response (SVR) during hepatitis C treatment.
Materials and methods.
We included patients with biopsy-proven chronic hepatitis C and ALT above the upper limit of normal, who received a standard treatment of pegylated interferon alfa-2a and ribavirin. The HCV-RNA concentration (limit of detection 20 IU/mL) was determined at days 0, 1, 2, 3, 4, 7, 14, 21 and monthly thereafter.
Results.
Among 46 patients who completed the trial, 30 (65%) had SVR. Low baseline viral load, IL28B genotype CC and absence of cirrhosis were statistically associated with SVR. In multivariate analysis only absence of cirrhosis and HCV-RNA negativity at day 14 were independent predictors for SVR. Eight patients who became HCV-RNA negative on day 14 as well as 13 of 14 patients (93%) with HCV-RNA levels of |
| doi_str_mv | 10.3109/00365521.2012.694905 |
| format | article |
| fullrecord | <record><control><sourceid>informahealthcare_pasca</sourceid><recordid>TN_cdi_informahealthcare_journals_10_3109_00365521_2012_694905</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3109_00365521_2012_694905</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-ba0d36ed1fc8465010313bd3e48dbeed96a3df3eed0a2223e4dbb8c87ae19de3</originalsourceid><addsrcrecordid>eNqFkc2KFDEUhYMoTjv6BiLZuKw2P_W7UYZGHWEYQQa3xa3kpitjdVIk6Wn6sXxDU_S04kZXCZfvnJucQ8hrztaSs-4dY7KuKsHXgnGxrruyY9UTsuIVE0XTsPYpWS1IsTAX5EWM94yxqim75-RCiLphDStX5OctbiHZB6TXm-_Ft9srKugB8UekYBIGap1NNgPeUW9oCghphy7ROaC2KkUa9zGBdajpgw1-8lurYKIB4-xdRJo8nXF7nCBlwrpsaTBkM5gMFAIoOE2DHSCLrcsAnfOyvCDSg00jVWOGraIjLvNkI928JM8MTBFfPZ6X5O7Tx7vNdXHz9fOXzdVNocqyTcUATMsaNTeqLeuKcSa5HLTEstUDou5qkNrIfGMghMhzPQytahtA3mmUl6Q82argYwxo-jnYHYRjz1m_FNCfC-iXAvpTAVn25iSb98MO9W_ROfEMvH0EIOakTACnbPzD1ZK1bc0z9-HEWWd82MHBh0n3CY6TD2eR_M9T3v_lMCJMaVQQsL_3--ByeP_-yy8hxroo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Christensen, Peer Brehm ; Krarup, Henrik Bygum ; Laursen, Alex Lund ; Madsen, Poul Henning ; Pedersen, Court ; Schlichting, Poul ; Orholm, Marianne ; Ring-Larsen, Helmer ; Bukh, Jens ; Krogsgaard, Kim</creator><creatorcontrib>Christensen, Peer Brehm ; Krarup, Henrik Bygum ; Laursen, Alex Lund ; Madsen, Poul Henning ; Pedersen, Court ; Schlichting, Poul ; Orholm, Marianne ; Ring-Larsen, Helmer ; Bukh, Jens ; Krogsgaard, Kim</creatorcontrib><description>Abstract
Objective.
The aim of this study was to examine the early viral kinetics as predictor for sustained virological response (SVR) during hepatitis C treatment.
Materials and methods.
We included patients with biopsy-proven chronic hepatitis C and ALT above the upper limit of normal, who received a standard treatment of pegylated interferon alfa-2a and ribavirin. The HCV-RNA concentration (limit of detection 20 IU/mL) was determined at days 0, 1, 2, 3, 4, 7, 14, 21 and monthly thereafter.
Results.
Among 46 patients who completed the trial, 30 (65%) had SVR. Low baseline viral load, IL28B genotype CC and absence of cirrhosis were statistically associated with SVR. In multivariate analysis only absence of cirrhosis and HCV-RNA negativity at day 14 were independent predictors for SVR. Eight patients who became HCV-RNA negative on day 14 as well as 13 of 14 patients (93%) with HCV-RNA levels of <1000 IU/mL at day 7 obtained a SVR. Among 8 of 18 (44%) genotype 1 and 4 patients with more than a one log drop in HCV-RNA titer at day 7, 75% achieved SVR.
Conclusions.
We observed a correlation between low HCV-RNA titers in week 2 and SVR during pegylated interferon/ribavirin-based treatment. This may help identify a group of patients for whom SVR may be obtained without the addition of directly acting antivirals, and thereby save the patients for unnecessary side effects and the health care system for additional costs.</description><identifier>ISSN: 0036-5521</identifier><identifier>EISSN: 1502-7708</identifier><identifier>DOI: 10.3109/00365521.2012.694905</identifier><identifier>PMID: 22670704</identifier><identifier>CODEN: SJGRA4</identifier><language>eng</language><publisher>Colchester: Informa Healthcare</publisher><subject>Adult ; Alanine Transaminase - blood ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; Drug Therapy, Combination ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Genotype ; Hepacivirus - genetics ; hepatitis C ; Hepatitis C, Chronic - blood ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - genetics ; Human viral diseases ; Humans ; Infectious diseases ; Interferon-alpha - therapeutic use ; Interferons ; Interleukins - genetics ; Liver Cirrhosis - virology ; Male ; Medical sciences ; Middle Aged ; pegylated interferon alfa-2a ; Pharmacology. Drug treatments ; Polyethylene Glycols - therapeutic use ; Predictive Value of Tests ; Recombinant Proteins - therapeutic use ; Ribavirin - therapeutic use ; ribavirin concentration ; RNA, Viral - blood ; Time Factors ; treatment ; Treatment Outcome ; Viral diseases ; Viral hepatitis ; viral kinetics ; Viral Load</subject><ispartof>Scandinavian journal of gastroenterology, 2012-09, Vol.47 (8-9), p.1115-1119</ispartof><rights>Informa Healthcare 2012</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-ba0d36ed1fc8465010313bd3e48dbeed96a3df3eed0a2223e4dbb8c87ae19de3</citedby><cites>FETCH-LOGICAL-c448t-ba0d36ed1fc8465010313bd3e48dbeed96a3df3eed0a2223e4dbb8c87ae19de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26308861$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22670704$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Christensen, Peer Brehm</creatorcontrib><creatorcontrib>Krarup, Henrik Bygum</creatorcontrib><creatorcontrib>Laursen, Alex Lund</creatorcontrib><creatorcontrib>Madsen, Poul Henning</creatorcontrib><creatorcontrib>Pedersen, Court</creatorcontrib><creatorcontrib>Schlichting, Poul</creatorcontrib><creatorcontrib>Orholm, Marianne</creatorcontrib><creatorcontrib>Ring-Larsen, Helmer</creatorcontrib><creatorcontrib>Bukh, Jens</creatorcontrib><creatorcontrib>Krogsgaard, Kim</creatorcontrib><title>Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C</title><title>Scandinavian journal of gastroenterology</title><addtitle>Scand J Gastroenterol</addtitle><description>Abstract
Objective.
The aim of this study was to examine the early viral kinetics as predictor for sustained virological response (SVR) during hepatitis C treatment.
Materials and methods.
We included patients with biopsy-proven chronic hepatitis C and ALT above the upper limit of normal, who received a standard treatment of pegylated interferon alfa-2a and ribavirin. The HCV-RNA concentration (limit of detection 20 IU/mL) was determined at days 0, 1, 2, 3, 4, 7, 14, 21 and monthly thereafter.
Results.
Among 46 patients who completed the trial, 30 (65%) had SVR. Low baseline viral load, IL28B genotype CC and absence of cirrhosis were statistically associated with SVR. In multivariate analysis only absence of cirrhosis and HCV-RNA negativity at day 14 were independent predictors for SVR. Eight patients who became HCV-RNA negative on day 14 as well as 13 of 14 patients (93%) with HCV-RNA levels of <1000 IU/mL at day 7 obtained a SVR. Among 8 of 18 (44%) genotype 1 and 4 patients with more than a one log drop in HCV-RNA titer at day 7, 75% achieved SVR.
Conclusions.
We observed a correlation between low HCV-RNA titers in week 2 and SVR during pegylated interferon/ribavirin-based treatment. This may help identify a group of patients for whom SVR may be obtained without the addition of directly acting antivirals, and thereby save the patients for unnecessary side effects and the health care system for additional costs.</description><subject>Adult</subject><subject>Alanine Transaminase - blood</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Genotype</subject><subject>Hepacivirus - genetics</subject><subject>hepatitis C</subject><subject>Hepatitis C, Chronic - blood</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - genetics</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Interferons</subject><subject>Interleukins - genetics</subject><subject>Liver Cirrhosis - virology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>pegylated interferon alfa-2a</subject><subject>Pharmacology. Drug treatments</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Predictive Value of Tests</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Ribavirin - therapeutic use</subject><subject>ribavirin concentration</subject><subject>RNA, Viral - blood</subject><subject>Time Factors</subject><subject>treatment</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>viral kinetics</subject><subject>Viral Load</subject><issn>0036-5521</issn><issn>1502-7708</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqFkc2KFDEUhYMoTjv6BiLZuKw2P_W7UYZGHWEYQQa3xa3kpitjdVIk6Wn6sXxDU_S04kZXCZfvnJucQ8hrztaSs-4dY7KuKsHXgnGxrruyY9UTsuIVE0XTsPYpWS1IsTAX5EWM94yxqim75-RCiLphDStX5OctbiHZB6TXm-_Ft9srKugB8UekYBIGap1NNgPeUW9oCghphy7ROaC2KkUa9zGBdajpgw1-8lurYKIB4-xdRJo8nXF7nCBlwrpsaTBkM5gMFAIoOE2DHSCLrcsAnfOyvCDSg00jVWOGraIjLvNkI928JM8MTBFfPZ6X5O7Tx7vNdXHz9fOXzdVNocqyTcUATMsaNTeqLeuKcSa5HLTEstUDou5qkNrIfGMghMhzPQytahtA3mmUl6Q82argYwxo-jnYHYRjz1m_FNCfC-iXAvpTAVn25iSb98MO9W_ROfEMvH0EIOakTACnbPzD1ZK1bc0z9-HEWWd82MHBh0n3CY6TD2eR_M9T3v_lMCJMaVQQsL_3--ByeP_-yy8hxroo</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Christensen, Peer Brehm</creator><creator>Krarup, Henrik Bygum</creator><creator>Laursen, Alex Lund</creator><creator>Madsen, Poul Henning</creator><creator>Pedersen, Court</creator><creator>Schlichting, Poul</creator><creator>Orholm, Marianne</creator><creator>Ring-Larsen, Helmer</creator><creator>Bukh, Jens</creator><creator>Krogsgaard, Kim</creator><general>Informa Healthcare</general><general>Taylor & Francis</general><general>Informa</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20120901</creationdate><title>Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C</title><author>Christensen, Peer Brehm ; Krarup, Henrik Bygum ; Laursen, Alex Lund ; Madsen, Poul Henning ; Pedersen, Court ; Schlichting, Poul ; Orholm, Marianne ; Ring-Larsen, Helmer ; Bukh, Jens ; Krogsgaard, Kim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-ba0d36ed1fc8465010313bd3e48dbeed96a3df3eed0a2223e4dbb8c87ae19de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Alanine Transaminase - blood</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Genotype</topic><topic>Hepacivirus - genetics</topic><topic>hepatitis C</topic><topic>Hepatitis C, Chronic - blood</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - genetics</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Interferons</topic><topic>Interleukins - genetics</topic><topic>Liver Cirrhosis - virology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>pegylated interferon alfa-2a</topic><topic>Pharmacology. Drug treatments</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Predictive Value of Tests</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Ribavirin - therapeutic use</topic><topic>ribavirin concentration</topic><topic>RNA, Viral - blood</topic><topic>Time Factors</topic><topic>treatment</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>viral kinetics</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Christensen, Peer Brehm</creatorcontrib><creatorcontrib>Krarup, Henrik Bygum</creatorcontrib><creatorcontrib>Laursen, Alex Lund</creatorcontrib><creatorcontrib>Madsen, Poul Henning</creatorcontrib><creatorcontrib>Pedersen, Court</creatorcontrib><creatorcontrib>Schlichting, Poul</creatorcontrib><creatorcontrib>Orholm, Marianne</creatorcontrib><creatorcontrib>Ring-Larsen, Helmer</creatorcontrib><creatorcontrib>Bukh, Jens</creatorcontrib><creatorcontrib>Krogsgaard, Kim</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Scandinavian journal of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Christensen, Peer Brehm</au><au>Krarup, Henrik Bygum</au><au>Laursen, Alex Lund</au><au>Madsen, Poul Henning</au><au>Pedersen, Court</au><au>Schlichting, Poul</au><au>Orholm, Marianne</au><au>Ring-Larsen, Helmer</au><au>Bukh, Jens</au><au>Krogsgaard, Kim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C</atitle><jtitle>Scandinavian journal of gastroenterology</jtitle><addtitle>Scand J Gastroenterol</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>47</volume><issue>8-9</issue><spage>1115</spage><epage>1119</epage><pages>1115-1119</pages><issn>0036-5521</issn><eissn>1502-7708</eissn><coden>SJGRA4</coden><abstract>Abstract
Objective.
The aim of this study was to examine the early viral kinetics as predictor for sustained virological response (SVR) during hepatitis C treatment.
Materials and methods.
We included patients with biopsy-proven chronic hepatitis C and ALT above the upper limit of normal, who received a standard treatment of pegylated interferon alfa-2a and ribavirin. The HCV-RNA concentration (limit of detection 20 IU/mL) was determined at days 0, 1, 2, 3, 4, 7, 14, 21 and monthly thereafter.
Results.
Among 46 patients who completed the trial, 30 (65%) had SVR. Low baseline viral load, IL28B genotype CC and absence of cirrhosis were statistically associated with SVR. In multivariate analysis only absence of cirrhosis and HCV-RNA negativity at day 14 were independent predictors for SVR. Eight patients who became HCV-RNA negative on day 14 as well as 13 of 14 patients (93%) with HCV-RNA levels of <1000 IU/mL at day 7 obtained a SVR. Among 8 of 18 (44%) genotype 1 and 4 patients with more than a one log drop in HCV-RNA titer at day 7, 75% achieved SVR.
Conclusions.
We observed a correlation between low HCV-RNA titers in week 2 and SVR during pegylated interferon/ribavirin-based treatment. This may help identify a group of patients for whom SVR may be obtained without the addition of directly acting antivirals, and thereby save the patients for unnecessary side effects and the health care system for additional costs.</abstract><cop>Colchester</cop><pub>Informa Healthcare</pub><pmid>22670704</pmid><doi>10.3109/00365521.2012.694905</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0036-5521 |
| ispartof | Scandinavian journal of gastroenterology, 2012-09, Vol.47 (8-9), p.1115-1119 |
| issn | 0036-5521 1502-7708 |
| language | eng |
| recordid | cdi_informahealthcare_journals_10_3109_00365521_2012_694905 |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | Adult Alanine Transaminase - blood Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - therapeutic use Biological and medical sciences Drug Therapy, Combination Female Gastroenterology. Liver. Pancreas. Abdomen Genotype Hepacivirus - genetics hepatitis C Hepatitis C, Chronic - blood Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - genetics Human viral diseases Humans Infectious diseases Interferon-alpha - therapeutic use Interferons Interleukins - genetics Liver Cirrhosis - virology Male Medical sciences Middle Aged pegylated interferon alfa-2a Pharmacology. Drug treatments Polyethylene Glycols - therapeutic use Predictive Value of Tests Recombinant Proteins - therapeutic use Ribavirin - therapeutic use ribavirin concentration RNA, Viral - blood Time Factors treatment Treatment Outcome Viral diseases Viral hepatitis viral kinetics Viral Load |
| title | Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T17%3A32%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Negative%20HCV-RNA%202%20weeks%20after%20initiation%20of%20treatment%20predicts%20sustained%20virological%20response%20to%20pegylated%20interferon%20alfa-2a%20and%20ribavirin%20in%20patients%20with%20chronic%20hepatitis%20C&rft.jtitle=Scandinavian%20journal%20of%20gastroenterology&rft.au=Christensen,%20Peer%20Brehm&rft.date=2012-09-01&rft.volume=47&rft.issue=8-9&rft.spage=1115&rft.epage=1119&rft.pages=1115-1119&rft.issn=0036-5521&rft.eissn=1502-7708&rft.coden=SJGRA4&rft_id=info:doi/10.3109/00365521.2012.694905&rft_dat=%3Cinformahealthcare_pasca%3E10_3109_00365521_2012_694905%3C/informahealthcare_pasca%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c448t-ba0d36ed1fc8465010313bd3e48dbeed96a3df3eed0a2223e4dbb8c87ae19de3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/22670704&rfr_iscdi=true |